Following the world-breaking first cloning of a mammal (Dolly the Sheep) at the Roslin Institute within the University of Edinburgh (UK) in 1997, there was worldwide interest to access Roslin’s technology and expertise. RoslinCT was established in 2006 to translate this cutting-edge science and apply it to the development of human medicines.
RoslinCT, as one of the first in the world to produce clinical-grade human pluripotent stem cells, has a strong focus on science and innovation. In collaboration with our partners, RoslinCT is supporting the development and future commercialization of cell therapies based on a broad range of cell types with an advanced program utilizing CRISPR-edited stem cell-based therapy.
A significant part of developing its global services more recently, has been the acquisition of a large state-of-the-art facility in Boston. In addition to allowing the company to expand its array of services, this has also enhanced expertise, resources, and transatlantic cGMP manufacturing capabilities to support the development and commercialization of advanced cell & gene therapies worldwide.
Throughout its history, RoslinCT has prided itself on not overpromising, but delivering, on behalf of its clients, advanced cell and gene products acceptable to regulators around the world.
